Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.

NCT00409188 is registered in ClinicalTrials.gov with EMD Serono as lead sponsor.

NCT NCT00409188
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00409188 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center Phase III Randomized, Double-blind Placebo-controlled Study of the Cancer Vaccine Stimuvax® (L-BLP25 or BLP25 Liposome Vaccine) in Non-small Cell Lung Cancer (NSCLC) Subjects With Unresectable Stage III Disease.
Lead sponsor
EMD Serono
Phase
Phase 3
Overall status
Completed
Start date
January 31, 2007
Completion date
April 30, 2015
Enrollment
1,513 (actual)
Sites
290

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer